Research Evaluating the Value of Augmenting Medication With Psychotherapy (REVAMP)
Depression, Depressive Disorder

About this trial
This is an interventional treatment trial for Depression
Eligibility Criteria
Inclusion Criteria Major depressive episode Depressive symptoms > 2 years without remission Hamilton Depression Scale (HAM-D) score > 20 Fluent in English Exclusion Criteria Psychotic disorders, bipolar disorder, post traumatic stress disorder, obsessive compulsive disorder, or eating disorder Serious, unstable, or terminal medical condition Axis II diagnosis of antisocial, schizotypal, or severe borderline personality disorder Previous treatment with CBASP Previous ineffective treatment with 4 of the medication treatments used in the study Substance abuse Pregnancy Not willing to end other psychiatric treatment
Sites / Locations
- University of Arizona
- Stanford University
- Emory University
- Weill-Cornell Medical College Payne Whitney Clinic
- SUNY- Stony Brook
- University of Pittsburgh
- Brown University
- University of Texas Southwestern Medical Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Active Comparator
CBASP
Brief Supportive Psychotherapy
Medication Only
Cognitive Behavioral System of Psychotherapy plus medication (Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine)
Brief Supportive Psychotherapy plus medication (Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine)
Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine